BRPI0920662A2 - oncostatina m como um reforço da atividade imunoestimulatória de células epiteliais humanas - Google Patents

oncostatina m como um reforço da atividade imunoestimulatória de células epiteliais humanas

Info

Publication number
BRPI0920662A2
BRPI0920662A2 BRPI0920662-0A BRPI0920662A BRPI0920662A2 BR PI0920662 A2 BRPI0920662 A2 BR PI0920662A2 BR PI0920662 A BRPI0920662 A BR PI0920662A BR PI0920662 A2 BRPI0920662 A2 BR PI0920662A2
Authority
BR
Brazil
Prior art keywords
oncostatin
epithelial cells
reinforcement
immunostimulatory activity
human epithelial
Prior art date
Application number
BRPI0920662-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Aldabe Arregui Rafael
González De La Tajada Iranzu
Esther Larrea Leoz María
María Prieto Valtueña Jesús
Sarobe Ugarriza Pablo
Original Assignee
Proyecto De Biomedicina Cima, S.L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto De Biomedicina Cima, S.L filed Critical Proyecto De Biomedicina Cima, S.L
Publication of BRPI0920662A2 publication Critical patent/BRPI0920662A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0920662-0A 2008-10-07 2009-10-06 oncostatina m como um reforço da atividade imunoestimulatória de células epiteliais humanas BRPI0920662A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200802835A ES2342529B1 (es) 2008-10-07 2008-10-07 Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
ESP200802835 2008-10-07
PCT/ES2009/070419 WO2010040882A1 (es) 2008-10-07 2009-10-06 Oncostatina m como potenciador de la actividad inmunoestimuladora de células epiteliales humanas

Publications (1)

Publication Number Publication Date
BRPI0920662A2 true BRPI0920662A2 (pt) 2018-06-26

Family

ID=41478601

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920662-0A BRPI0920662A2 (pt) 2008-10-07 2009-10-06 oncostatina m como um reforço da atividade imunoestimulatória de células epiteliais humanas

Country Status (11)

Country Link
US (1) US20110195047A1 (enExample)
EP (1) EP2345423A1 (enExample)
JP (1) JP2012504948A (enExample)
CN (1) CN102202690A (enExample)
AU (1) AU2009301067A1 (enExample)
BR (1) BRPI0920662A2 (enExample)
CA (1) CA2739670A1 (enExample)
ES (1) ES2342529B1 (enExample)
MX (1) MX2011003676A (enExample)
RU (1) RU2011118362A (enExample)
WO (1) WO2010040882A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102352368B (zh) * 2011-09-29 2013-12-04 苏州大学 Ing4与osm双基因共表达载体及其应用
US20130330761A1 (en) 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
CN105829893A (zh) * 2013-06-14 2016-08-03 西班牙格拉纳达大学 用于胰腺癌诊断及治疗响应的生物标记物
WO2015089380A2 (en) * 2013-12-12 2015-06-18 Celcuity Llc Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
CN104096219A (zh) * 2014-07-08 2014-10-15 武汉大学 Ⅱ型抑瘤素m受体（osmr）在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
EP3879269A3 (en) 2017-03-20 2021-11-17 Celcuity Inc. Methods of measuring signaling pathway activity for selection of therapeutic agents
MX2023004500A (es) 2020-10-19 2023-05-10 Zoetis Services Llc Anticuerpos contra el receptor beta de la oncostatina m canina y felina y usos de estos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
IL112768A (en) 1989-04-10 1998-06-15 Oncogen Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
RU2236251C2 (ru) * 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
EP1326961B1 (en) * 2000-09-15 2007-08-22 Ortho-McNeil Pharmaceutical, Inc. Compositions and methods for inducing specific cytolytic t cell responses
JP2004026768A (ja) 2002-06-27 2004-01-29 Kanagawa Acad Of Sci & Technol 肝疾患治療又は予防薬
AU2002953238A0 (en) * 2002-12-09 2003-01-02 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland In vitro immunization
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
RU2007130552A (ru) * 2005-01-10 2009-02-20 Рисерч Дивелопмент Фаундейшн (US) Рекомбинантные молекулы направленного действия для лечения рака
JP5328156B2 (ja) 2005-02-03 2013-10-30 マクロジェニックス ウエスト， インコーポレイテッド オンコスタチンｍレセプターに対する抗体
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.

Also Published As

Publication number Publication date
US20110195047A1 (en) 2011-08-11
EP2345423A1 (en) 2011-07-20
RU2011118362A (ru) 2012-11-20
CA2739670A1 (en) 2010-04-15
CN102202690A (zh) 2011-09-28
WO2010040882A1 (es) 2010-04-15
ES2342529A1 (es) 2010-07-07
AU2009301067A1 (en) 2010-04-15
JP2012504948A (ja) 2012-03-01
ES2342529B1 (es) 2011-05-11
MX2011003676A (es) 2011-05-02

Similar Documents

Publication Publication Date Title
BRPI0920662A2 (pt) oncostatina m como um reforço da atividade imunoestimulatória de células epiteliais humanas
BRPI1010957A2 (pt) variantes de celulase com expressão, atividade e/ou estabilidade aprimorada e uso das mesmas.
BRPI0813680A2 (pt) AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
FR2941231B1 (fr) Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
BRPI0913216A2 (pt) uso de um herpesvírus recombinante de perus, e, herpesvírus recombinante de perus.
BRPI0911351A2 (pt) estrutura de sent, e , prótese de válvula.
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
MX2012011840A (es) Estructuras multimericas especificas para ligado inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trial).
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
BRPI0816182A2 (pt) Agente para promoção de adesão celular endotelial corneana
HRP20150107T1 (xx) Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
BRPI0918789A2 (pt) variantes de beta-glicosidase tendo atividade melhorada, e uso das mesmas
WO2010144477A3 (en) Sulfonylurea modulators of endothelin receptor
WO2012031164A3 (en) Drug delivery by carbon nanotube arrays
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
WO2009149030A3 (en) Oral care compositions and methods
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
CR20110701A (es) Derivados de pirazoles, su preparacion y su aplicacion terapeutica.
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
BRPI1014125A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BR112012002596A2 (pt) formulações de polipeptídeo concentradas com viscodidade reduzida
BR112013005383A2 (pt) 'copoliamidas, processos de preparação da copoliamida e composiçaõ
BRPI0906727A2 (pt) Azaindol-3-carboxamidas cíclicas, sua preparação e seu uso como produtos farmacêuticos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2478 DE 03-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]